Strategies for Managing AEs, Patient Adherence in Acalabrutinib for Mantle Cell Lymphoma
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
In this study, the cutoff for biochemical adherence/nonadherence was a serum tamoxifen level of 60 ng/mL.
This observational cohort study found that BAAS questionnaire is not a suitable tool for monitoring whether older patients with mCRPC are adherent to their antiandrogen therapy; however, pill counting was effective.
This study investigated patient adherence and persistence with trifluridine/tipiracil combination and regorafenib regimens for metastatic colorectal cancer, and also addressed whether sequence of administration had an effect on patient adherence and persistence to the therapies.
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
An interesting finding from this study was that many of the reasons offered by patients either in support of or against TKI discontinuation related to the same topic areas.
Using separate indirect medication adherence measures, researchers determined adherence rates for patients with MM treated with oral immunomodulatory therapy.
A prospective pilot study investigated the impact of depression on adherence to oral anticancer therapy in older patients with a wide range of advanced solid tumors.
Oral therapy brings new challenges to oncology practices, because more responsibility of adherence is placed under patient and caregiver control.
Risk of nonadherence was lower for survivors reporting a usual source of care than those without